Passage Bio (PASG) Stock Price, News & Analysis

Company Overview

Passage Bio, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases of the central nervous system. The company uses adeno-associated virus (AAV) gene therapy platforms to deliver functional genes to target cells, with the goal of addressing the underlying causes of inherited neurological disorders.

Passage Bio’s development programs have included investigational therapies for conditions such as GM1 gangliosidosis, Krabbe disease and frontotemporal dementia. Its research and development activities have been supported by collaborations with the University of Pennsylvania’s Gene Therapy Program, which has contributed expertise in vector design, manufacturing and clinical development. As with other clinical-stage biotechnology companies, its product candidates remain subject to clinical testing and regulatory review and may not receive approval.

Founded in 2018 and headquartered in Philadelphia, Passage Bio has primarily served patients and research markets through its global clinical-development and biotechnology activities rather than through commercialized products. The company became publicly traded on the Nasdaq under the symbol PASG in 2020. Its programs, partnerships and corporate strategy may evolve as clinical data and regulatory developments become available.

Key Stats

• Today's Range: $4.11 to $4.44
• 50-Day Range: $4.12 to $5.04
• 52-Week Range: $3.29 to $20.00
• Volume: 17,049 shs
• Average Volume: 30,392 shs
• Market Capitalization: $12.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.25
• Consensus Rating: Hold

Passage Bio Stock Analysis - MarketRank™

Passage Bio scored higher than 43% of companies evaluated by MarketBeat, and ranked 601st out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Hold

Consensus Rating

Passage Bio has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on no strong buy ratings, 2 buy ratings, 6 hold ratings, and 1 sell rating.

Upside Potential

Passage Bio has a consensus price target of $13.25, representing about 221.6% upside from its current price of $4.12.

Amount of Analyst Coverage

Passage Bio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Passage Bio are expected to decrease in the coming year, from ($9.19) to ($9.72) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Passage Bio is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Passage Bio is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Passage Bio has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.17% of the float of Passage Bio has been sold short.

Short Interest Ratio / Days to Cover

Passage Bio has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Passage Bio has recently decreased by 4.56%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Passage Bio does not currently pay a dividend.

Dividend Growth

Passage Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

2 people have added Passage Bio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Passage Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.90% of the stock of Passage Bio is held by insiders.

Percentage Held by Institutions

53.48% of the stock of Passage Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PASG
• CIK: 1787297
• Web: www.passagebio.com
• Phone: (267) 866-0312
• Fax: N/A
• Employees: 130
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Passage Bio: $13.25
• High Price Target: $23.00
• Low Price Target: $7.00
• Potential Upside/Downside: +231.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.11
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($11.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$45.52 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -218.59%
• Return on Assets: -72.93%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.22
• Quick Ratio: 1.22

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.90 per share
• Price / Book: 0.68

Miscellaneous

• Outstanding Shares: 3,220,000
• Free Float: 3,060,000
• Market Cap: $12.88 million
• Optionable: No Data
• Beta: 1.40